Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,823 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10205
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
· J Clin Oncol · 2013 · PMID 23816960 · validated civic_curation pubmed
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
· Lancet Oncol · 2014 · PMID 24439929 · validated civic_curation pubmed
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
· Lancet Oncol · 2015 · PMID 25589191 · validated civic_curation pubmed
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
· J Clin Oncol · 2012 · PMID 22493419 · validated civic_curation pubmed
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
· Breast · 2015 · PMID 26255196 · validated civic_curation pubmed
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
· J Clin Oncol · 2010 · PMID 20124187 · validated civic_curation pubmed
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Showing 26–50 of 384 publications

← Previous
1
2
3
…
16
Next →

· Lancet Oncol · 2016 · PMID 26822398 · validated civic_curation pubmed

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.

· Cancer Immunol Res · 2014 · PMID 24989892 · validated civic_curation pubmed

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

· Am J Obstet Gynecol · 2005 · PMID 15746676 · validated civic_curation pubmed

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

· N Engl J Med · 2006 · PMID 17192538 · validated civic_curation pubmed

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

· J Clin Oncol · 2009 · PMID 19289619 · validated civic_curation pubmed

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

· Lancet Oncol · 2014 · PMID 24793816 · validated civic_curation pubmed

Trastuzumab emtansine for HER2-positive advanced breast cancer.

· N Engl J Med · 2012 · PMID 23020162 · validated civic_curation pubmed

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

· J Clin Oncol · 2016 · PMID 27091708 · validated civic_curation pubmed

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

· N Engl J Med · 2012 · PMID 22149875 · validated civic_curation pubmed

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

· Lancet · 2012 · PMID 22257673 · validated civic_curation pubmed

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.

· Cancer Res · 2013 · PMID 23204226 · validated civic_curation pubmed

Integrative clinical genomics of advanced prostate cancer.

· Cell · 2015 · PMID 26000489 · validated cbioportal_study pubmed

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.

· Cancer · 2013 · PMID 22810899 · validated civic_curation pubmed

MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.

· Sci Rep · 2016 · PMID 27819322 · validated civic_curation pubmed

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

· J Clin Oncol · 2011 · PMID 21172893 · validated civic_curation pubmed

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18682506 · validated civic_curation pubmed

The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma.

· Clin Cancer Res · 2006 · PMID 16467086 · validated civic_curation pubmed

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

· Lancet Oncol · 2012 · PMID 22285168 · validated civic_curation pubmed

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

· Oncotarget · 2017 · PMID 28103578 · validated civic_curation pubmed